Press Releases

The global ceftriaxone market share is expected to grow at a 3.2% CAGR during the forecast period. Ceftriaxone is an antibiotic that is used to treat a wide range of bacterial infections. This medication belongs to a category of drugs called as cephalosporin antibiotics which has a very long half-life compared to other cephalosporins. It is highly penetrable into the eyes, inner ear, and meninges and is usually used for intra-abdominal infections, urinary tract infections, acute bacterial otitis media, pneumonia, and endocarditis. It works by inhibiting bacterial growth. Because of the increased risk of side effects, this drug is not recommended for use in newborns with high blood bilirubin levels or premature infants. Rising prevalence of urinary tract infections, increased public awareness, and an increase in the geriatric population susceptible to bacterial diseases are expected to boost global ceftriaxone market position in the near future. Nevertheless, in order to address the growing demand for ceftriaxone around the world, manufacturers are working to develop generic versions of the drug.

In November 2022, Orchid Pharma completed global clinical trials of a drug product that is a combination of Enmetazobactam with Cefepime. This is an injectable product, which is highly effective to treat complex Urinary Tract Infections (cUTI).

Bowse 43 market data Tables and 30 Figures spread through 200 Pages and in-depth TOC on " Ceftriaxone Market by Indication (Intra-Abdominal Infections, Endocarditis, Meningitis, Urinary Tract Infections, Acute Bacterial Otitis Media, Pneumonia, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region - Global Forecast to 2030

By indication, the Urinary Tract Infections segment is anticipated to have significant growth during the forecast period.

Based on Indication, the Global Ceftriaxone Market is segmented into Intra-Abdominal Infections, Endocarditis, Meningitis, Urinary Tract Infections, Acute Bacterial Otitis Media, Pneumonia, and Others. UTIs are also known as bladder infections. UTIs are common, especially in women. More than half of women are expected to get at least one UTI at some point in their life. These infections are dangerous and severe. It is projected that increased use of ceftriaxone in the treatment of urinary tract infections will accelerate significant growth of the ceftriaxone market.

Global Ceftriaxone Market Segmentation Analysis

Discover More About This Report, Download A Free Sample Copy of the Global Ceftriaxone Market

“APAC is anticipated to significant market share in the Ceftriaxone Market during the forecast period.”

During the projection period, APAC is anticipated to experience significant growth. Asia-Pacific nations like China and India are seeing an increase in demand for ceftriaxone injection as a result of the region's high prevalence of chronic diseases and growing demand for efficient treatment options.

Some of the major players in the global Ceftriaxone industry include Hikma Pharmaceuticals PLC, Qilu Pharmaceutical Co. Ltd., Novartis AG, Baxter, Aurobindo Pharma, ACS Dobfar S.p.A., OrchidPharma Ltd., Nectar Lifesciences Ltd., Lupin Pharmaceuticals, Inc., and Virchow Healthcare Pvt. Ltd.

Scope of the Report

Global Ceftriaxone Market Coverage

Indication Insight and Forecast 2018-2030

• Intra-Abdominal Infections
• Endocarditis
• Meningitis
• Urinary Tract Infections
• Acute Bacterial Otitis Media
• Pneumonia
• Others

Distribution Channel Insight and Forecast 2018-2030

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Geographical Segmentation

Ceftriaxone Market by Region

North America

• By Indication
• By Distribution Channel
• By Country – U.S., Canada, and Mexico

Europe

• By Indication
• By Distribution Channel
• By Country – Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe

Asia-Pacific (APAC)

• By Indication
• By Distribution Channel
• By Country – China, Japan, India, South Korea, and Rest of Asia-Pacific

Rest of the World (RoW)

• By Indication
• By Distribution Channel
• By Country – Brazil, Saudi Arabia, South Africa, U.A.E., and Other Countries